Rhythm Pharmaceuticals (RYTM) Non-Current Deferred Tax Liability (2021)
Rhythm Pharmaceuticals (RYTM) posted quarterly Non-Current Deferred Tax Liability of $8.0 million for Q3 2021, down 52.96% quarter-over-quarter from $17.0 million in Q2 2021.
Powered by 
Analysis
Rhythm Pharmaceuticals (RYTM) Non-Current Deferred Tax Liability (2021) Analysis & Trends
Rhythm Pharmaceuticals (RYTM) has reported Non-Current Deferred Tax Liability for 1 consecutive years, with $8.0 million the latest figure, recorded in Q3 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn |
| 10 | Rhythm Pharmaceuticals | 7.04 Bn | 6.71 Bn | 62.32 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2021 | 7.99 Mn |
| Jun 30, 2021 | 16.98 Mn |
| Mar 31, 2021 | 22.01 Mn |